Phase 1 HIV and AIDS Trial, Recruiting NCT06513819 Sponsor: Yale University Condition: HIV and AIDS
Back to Hiv Aids

Phase 1 HIV and AIDS Trial, Recruiting

NCT06513819
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are living with HIV.
  • You have visited a local VA (Veterans Affairs) healthcare site at least once in the past year.
  • A recent alcohol screening questionnaire (called the AUDIT-C) showed that you currently drink alcohol.
  • You are currently taking 5 or more medications (not counting HIV treatment medications), and at least one of those medications is from a specific group — such as benzodiazepines (anxiety/sedative medications), opioids (pain medications), muscle relaxants, sleeping pills, or certain antidepressants called SSRIs.

Who may not be able to join:

  • You are currently admitted to a hospital or inpatient facility.
  • You have been diagnosed with Alcohol Use Disorder (AUD) at any point in the past 12 months.
  • During the screening process, an alcohol symptoms checklist shows that you may have moderate or severe Alcohol Use Disorder.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Amy C Justice, MD, PhD, Yale University

Phone: 203-932-5711

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Registry
ClinicalTrials.gov
Start date
15 January 2025
Est. completion
1 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Feasibility: Ability to meet enrollment target of 100 participants; Feasibility: Ability to deliver the complete intervention; Feasibility:Percentage of Completion of Study Items; Acceptability: comfort, comprehensibility/helpfulness of content; Acceptability: acceptability of PEth tests

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov